Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial by McGuire, Darren K. et al.
Copyright 2016 American Medical Association. All rights reserved.
Association Between Sitagliptin Use and Heart Failure
Hospitalization and Related Outcomes
in Type 2 DiabetesMellitus
Secondary Analysis of a Randomized Clinical Trial
Darren K. McGuire, MD, MHSc; Frans Van deWerf, MD, PhD; Paul W. Armstrong, MD; Eberhard Standl, MD, PhD;
Joerg Koglin, MD; Jennifer B. Green, MD; M. Angelyn Bethel, MD; Jan H. Cornel, MD;
Renato D. Lopes, MD, MHS, PhD; Sigrun Halvorsen, MD; Giuseppe Ambrosio, MD; John B. Buse, MD;
Robert G. Josse, MBBS; JohnM. Lachin, ScD; Michael J. Pencina, PhD; Jyotsna Garg, MS; Yuliya Lokhnygina, PhD;
Rury R. Holman, MBChB; Eric D. Peterson, MD, MPH; for the Trial Evaluating Cardiovascular OutcomesWith
Sitagliptin (TECOS) Study Group
IMPORTANCE Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor
(DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The
DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and
secondary composite atherosclerotic cardiovascular (CV) outcomes in the Trial Evaluating
Cardiovascular OutcomesWith Sitagliptin (TECOS).
OBJECTIVE To assess the association of sitagliptin use with hospitalization for HF (hHF) and
related outcomes.
DESIGN, SETTING, AND PARTICIPANTS TECOSwas a randomized, double-blind,
placebo-controlled study evaluating the CV safety of sitagliptin vs placebo, each added to
usual antihyperglycemic therapy and CV care among patients with T2DM and prevalent
atherosclerotic vascular disease. Themedian follow-up was 2.9 years. The setting was 673
sites in 38 countries. Participants included 14 671 patients with T2DM and atherosclerotic
vascular disease. The study dates were December 2008 throughMarch 2015.
INTERVENTIONS Patients were randomized to sitagliptin vs placebo added to standard care.
MAIN OUTCOMES ANDMEASURES Prespecified secondary analyses compared the effect on
hHF, hHF or CV death, and hHF or all-cause death composite outcomes overall and in
prespecified subgroups. Supportive analyses included total hHF events (first plus recurrent)
and post-hHF death. Meta-analyses evaluated DPP4i effects on hHF and on hHF or CV death.
RESULTS Of 14 671 patients, 7332 were randomized to sitagliptin and 7339 to placebo.
Hospitalization for HF occurred in 3.1% (n = 228) and 3.1% (n = 229) of the sitagliptin and
placebo groups, respectively (unadjusted hazard ratio, 1.00; 95% CI, 0.83-1.19). There was
also no difference in total hHF events between the sitagliptin (n = 345) and placebo (n = 347)
groups (unadjusted hazard ratio, 1.00; 95% CI, 0.80-1.25). Post-hHF all-cause death was
similar in the sitagliptin and placebo groups (29.8% vs 28.8%, respectively), as was CV death
(22.4% vs 23.1%, respectively). No heterogeneity for the effect of sitagliptin on hHFwas
observed in subgroup analyses across 21 factors (P > .10 for all interactions). Meta-analysis of
the hHF results from the 3 reported DPP4i CV outcomes trials revealedmoderate
heterogeneity (I2 = 44.9, P = .16).
CONCLUSIONS AND RELEVANCE Sitagliptin use does not affect the risk for hHF in T2DM, both
overall and among high-risk patient subgroups.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00790205
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T ype 2 diabetesmellitus (T2DM) is associatedwithmul-tiple cardiovascular (CV) complications, possibly exac-erbated by certain antihyperglycemic therapies. Be-
cause of these latter concerns, US and European regulatory
guidance calls for rigorous CV safety assessment of all antihy-
perglycemicmedications developed for T2DM.1While the fo-
cus of such CV safety assessment has been on the composite
outcomesofCVdeath, acute coronary syndromes, and stroke,
heart failure (HF) has emerged as an increasingly important
consideration.2 Thediagnosis ofHF is a risk factor for T2DM,3
and T2DM is associated with an approximate 30% increased
risk of hospitalization for HF (hHF) in contemporary cohorts,
withworse prognosis of patientswithHF to a similar extent.4
Moreover, the use of some antihyperglycemic medications
has been associated with new or worsening HF, such as the
thiazolidinediones,5,6 aswell asdual peroxisomeproliferator–
activated receptor α and γ agonists.7,8
More recently,dipeptidylpeptidase4 inhibitor (DPP4i)use
hasbeenassociatedwith increasedhHFrisk,withongoingun-
certainty regarding the validity of the findings and their clini-
cal implications.9 Specifically, saxagliptin usewas associated
with a significant increase in hHF risk in the Saxagliptin
Assessment of Vascular Outcomes Recorded in Patients With
Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53
(SAVOR-TIMI53) trial.10Alogliptinusewasalsoassociatedwith
a numerically higher but not statistically significant in-
creased risk forhHF in theExaminationofCardiovascularOut-
comesWith Alogliptin vs Standard of Care (EXAMINE) trial.11
Meta-analyses12,13 of these and other DPP4i investigations
suggest that these agentsmay be associatedwith up to a 25%
increased risk for hHF.
The Trial Evaluating Cardiovascular OutcomesWith Sita-
gliptin (TECOS) is the third completedDPP4i, large-scale, ran-
domized CV outcomes trial. Overall, TECOS results demon-
strated that sitagliptinwasnoninferior to placebowith regard
to its primary and secondary composite CV outcomes.14 This
report explores in-depth potential associations of sitagliptin
usewithhHFandassociatedCVclinical outcomes, eitherover-
allor inkeypatientsubgroupsaccordingtoaprespecifiedanaly-
sis plan. The additive TECOS evidence with respect to DPP4i
effects on hHF risk is also used to place these findings into a
new overall context.
Methods
Study Design, Population, and Oversight
The design, protocol, Consolidated Standards of Reporting
Trials diagram, and primary results of TECOS have been pre-
viouslypublished.14,15 Thepresent study is aprespecified sec-
ondary analysis of TECOS, which was a randomized, double-
blind,event-drivenstudyevaluating theCVsafetyof sitagliptin
vsplacebo,eachaddedtousualantihyperglycemic therapyand
CV care amongpatientswith T2DMandprevalent atheroscle-
rotic vascular disease. TECOSwasdesignedand conductedby
theDuke Clinical Research Institute and theUniversity of Ox-
fordDiabetes Trials Unit in an academically independent col-
laborationwith the sponsor (MerckSharp&DohmeCorp). The
databasewas locatedatand independentlyverifiedbytheDuke
ClinicalResearch Institute.Theprotocol14wasapprovedby the
ethics committees associatedwith all participating trial sites,
andall participantsprovidedwritten informedconsent for trial
participation.
Study Population
Eligible patients had T2DM and prevalent coronary, cerebro-
vascular, or peripheral atherosclerotic vascular disease; were
50yearsorolder; andhadabaselineglycatedhemoglobin (A1c)
level of 6.5% to 8.0% on stable antihyperglycemic medica-
tion. Trial exclusions included the use of a DPP4i, glucagon-
like peptide 1 receptor agonists (GLP-1 RAs), or rosiglitazone
during the preceding 3 months; 2 or more episodes of hypo-
glycemia requiring third-party assistance in the previous 12
months; or anestimatedglomerular filtration rate less than30
mL/min/1.73 m2 at baseline. Patients with previous HF were
not excluded.
Randomization and StudyMedication
Participantswere randomlyassigned 1:1 to treatmentwith 100
mg daily of sitagliptin (50 mg daily if the baseline estimated
glomerular filtration rate was between 30 and <50 mL/min/
1.73m2) ormatching placebo, with predefined dosage adjust-
ments throughout the trial based on changes in the estimated
glomerular filtration rate.15 The A1c level was measured lo-
cally at enrollment, at 4 and 8 months, and then annually.
Open-label addition or titration of antihyperglycemic medi-
cations, other than a DPP4i or GLP-1 RA, was encouraged
throughout the trial, targeting A1c levels in accord with re-
gional standards of care and individualized goals.
Outcomes
PrespecifiedHF-relatedoutcomes included the timeto the first
hHF, the time to the first event of hHF or CV death, the time
to the first event of hHF or all-cause death, total hHF events
(including recurrent hHF), and the time to the first hHF in
subgroup analyses by 21 factors of interest, of which 16 were
prespecified in the main trial statistical analysis plan and 5
were addedposthoc (eAppendix 1 in theSupplement).Among
patients with hHF, post-hHF death was also summarized by
Key Points
Question What is the effect of sitagliptin use on risk for
hospitalization for heart failure and related outcomes?
Findings This randomized, placebo-controlled clinical trial
included 14 671 adults with type 2 diabetes mellitus and prevalent
atherosclerotic vascular disease. In secondary analyses, over a
median follow-up of 2.9 years, there were no significant
differences between sitagliptin vs placebo for the risk of
hospitalization for heart failure (3.1% vs 3.1%, respectively) or for
the composite of hospitalization for heart failure or cardiovascular
death (7.3% vs 7.2%, respectively).
Meaning Sitagliptin use has a neutral effect on hospitalization for
heart failure risk in patients with type 2 diabetes mellitus at high
cardiovascular risk.
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treatment group and was defined as deaths occurring either
during the index hHFor at any time thereafter,with CVdeath
and all-cause death reported. An independent clinical events
committee masked to treatment allocation adjudicated all
events of hHF and death using end point definitions as previ-
ously reported,15 derived from definitions of the Standard-
izedData Collection for Cardiovascular Trials Initiativework-
ing group (http://www.clinpage.com/images/uploads
/endpoint-defs_11-16-2010.pdf).ThehHFoutcomewasdefined
as at least 12-hour inpatient or emergencydepartment care for
HF, with clinical manifestation of HF that included at least 1
of the following: new or worsening dyspnea, orthopnea,
paroxysmal nocturnal dyspnea, edema, pulmonary basilar
crackles, jugular venous distension, or radiological evidence
ofworseningHF, togetherwithadditionalor increased therapy,
including intravenous treatment with diuretic, inotrope, or
vasodilator therapy, or the use of a mechanical or surgical
intervention (mechanical circulatory support, heart
transplantation, or ventricular pacing to improve cardiac
function)or theuseofultrafiltration,hemofiltration,ordialysis
specificallydirectedat treatmentofHF (see the clinical events
committee definitions and process in eAppendix 2 in the
Supplement).
Statistical Analysis
Baseline characteristics for the randomized population were
summarized using the mean ±1 SD or the median and inter-
quartile range for quantitativedata andasproportions for cat-
egoricaldata.The time to the first occurrenceofhHFwasapre-
specifiedsecondaryanalysis in theoriginalTECOSprotocoland
statistical analysis plan.15 In response to the hHF signals re-
ported by the SAVOR-TIMI 53 and EXAMINEDPP4i trials dur-
ing the conduct of TECOS, additional exploratory hHF analy-
seswereplannedprospectivelyandbefore trial completionand
unmasking in a supplementary HF statistical analysis plan
(eAppendix 1 in theSupplement) to further investigate thepo-
tential effect of sitagliptin use on hHF-related outcomes.
Asper the original trial statistical analysis plan,14 the time
to the first occurrence of hHFwas evaluated using a Cox pro-
portional hazards regression model that included treatment
andhistoryofHFasexplanatory factors,with regionasa strati-
fication factor, when analyzing the intent-to-treat popula-
tion.Analyses added in the supplementalHF statistical analy-
sis plan included similar methods for analysis of the time to
the composite of the first hHFor CVdeath or hHFor all-cause
death, unadjusted analysis of the time to the first hHFand the
hHForCVdeath composite, and subgroupanalyses of hHFby
key prespecified baseline characteristics, including preva-
lent HF at baseline. Exposure times of all patients were
censoredat thedate theywere last knowntobe freeof all com-
ponents of the individual and composite outcomes analyzed.
ThemethodbyAndersenandGill16wasused toanalyzeall first
plus recurrent hHF events. Interaction terms in the Cox pro-
portional hazards regression models were used to assess
heterogeneity of the effect of sitagliptin vs placeboon the risk
of hHF outcomes among each subgroup analyzed. All analy-
ses were performed by Duke Clinical Research Institute stat-
isticians (M.J.P., J.G., and Y.L.) independent of the sponsor
using a softwareprogram (SAS, version9.4; SAS Institute Inc).
Meta-analyses using random-effects models on summative
datawereperformedforhHFoutcomesandthecompositeout-
come of hHF or CV deathwithout adjustment for baselineHF
using data from SAVOR-TIMI 53, EXAMINE, and TECOS with
a software program (Comprehensive Meta-Analysis Soft-
ware, version 2.0; Biostat, Inc), with heterogeneity assessed
among studies using the Cochran Q test and I2 index.
Results
Study Patients
The study setting was 673 sites in 38 countries. Of 14671 pa-
tients in the intent-to-treat population randomized between
December 16, 2008, and July 31, 2012, a total of 7332were as-
signed to sitagliptin and 7339 to placebo. Among the 2643pa-
tients (18.0%) with previous HF at trial entry, 1303 were as-
signed to sitagliptin and 1340 to placebo. During a median
follow-up surveillance for fatal plus nonfatal outcomes of 2.9
years (interquartile range, 1.4-5.7 years), 95.1% of sitagliptin-
assigned and 94.1% of placebo-assigned patients completed
the study, with 26.1% and 27.5%, respectively, discontinuing
studymedication prematurely. End-of-study vital statuswas
obtainedon97.5%ofpatients.Overall, 457patients (3.1%)had
at least 1 hHFevent,with baseline characteristics stratified by
those with vs without hHF events listed in Table 1. Baseline
data for the subset of patients with previous HF, stratified by
randomized treatment assignment, are listed in eTable 1 in the
Supplement. There was no difference between the random-
ized treatment groups in bloodpressure, heart rate, orweight
throughout the trial (eFigure 1 in the Supplement).
HF-Related Outcomes
TheHF-relatedoutcomesby randomized treatment groupare
summarized inTable 2 andFigure 1. The rate of a first hHFdid
notdiffer between thegroups, occurring in228patients (3.1%)
in the sitagliptin group and 229 patients (3.1%) in the placebo
group, with an unadjusted hazard ratio (HR) of 1.00 (95% CI,
0.83-1.19) (Table2andFigure 1A).TheHRwasunchangedwith
adjustment for regionofenrollmentandbaselineHF(HR, 1.00;
95%CI,0.83-1.20)and in fullyadjustedanalyses (HR, 1.02;95%
CI, 0.83-1.26). There was also no difference between sita-
gliptin vs placebo for the composite outcomes of hHF or CV
death (538 vs 525 events; HR, 1.02, 95% CI, 0.90-1.14)
(Figure 1B) or hHF or all-cause death (685 vs 682 events; HR,
1.00; 95% CI, 0.90-1.11) (Figure 1C).
The numbers of patients with multiple hHF events were
similar between the sitagliptin and placebo groups (63 vs 69,
respectively) (Table 2). The cumulativenumber of hHFevents
(firstplus recurrent)wasnotdifferentbetween thegroups (345
vs 347, respectively; HR, 1.00; 95% CI, 0.80-1.25). There was
no evidence for heterogeneity of randomized treatment ef-
fect by the time to hHF, with a nonsignificant treat-
ment × time interaction (P = .51). Among the subset of pa-
tients with previous HF at baseline, there were no significant
differencesobservedbetween the treatmentgroups inhHF,CV
death, or the composite of the 2.
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Death during or after hHF did not differ by randomized
group (Table 2), with CV death occurring in 51 of 228 sita-
gliptinpatients (22.4%)and53of 229placebopatients (23.1%).
All-cause death occurred in 68 of 228 sitagliptin patients
(29.8%) and 66 of 229 placebo patients (28.8%).
As shown inFigure 2, the rate of hHF varied substantially
across subgroupsdefinedbybaseline characteristics butwith
no heterogeneity of effect for sitagliptin vs placebo on hHF
(P > .10 for all interactions). Similar data for subgroup analy-
ses by randomized assignment for the composite outcome of
hHF or CV death are shown in eFigure 2 in the Supplement,
likewise with no evidence of heterogeneity of effect (P > .05
for all interactions).
For comparison across the 3 reported DPP4i CV out-
comes trials, baseline characteristics of the SAVOR-TIMI 53,
EXAMINE, and TECOS study populations are listed in eTable
2 in theSupplement,demonstrating substantial similarity.The
pooled estimate for the effect of aDPP4i vs placebo onhHF in
these 3 largeCVoutcomes trials (Figure 3A) showedanumeri-
cally increased HR of 1.14 (95% CI, 0.97-1.34), with moderate
heterogeneity (P = .16, I2 = 44.9). The pooled estimate for the
hHForCVdeath composite (Figure 3B) showedno significant
difference between the DPP4i and placebo groups (HR, 1.06;
95% CI, 0.98-1.15), with minimal heterogeneity (P = .36,
I2 = 1.29).
Discussion
In patientswith T2DMandprevalent atherosclerotic vascular
diseaseparticipating in theTECOSglobal, randomizedCVout-
comes trial, sitagliptin compared with placebo did not affect
the risk for hHF or for the composite hHF or CV death or hHF
orall-causedeathoutcomes.Therewasalsono increasedriskof
HFobserved inanysubgroupanalyzed, includingthoseathigh-
est risk forhHF, suchaspatientswithpreviousHF,kidneydys-
function, concomitant insulinuse, andhighestA1c level, aswell
as the elderly.
Table 1. Baseline Characteristics of Patients in the TECOS Intent-to-Treat
Population, Stratified by ThoseWith vsWithout First Hospitalization for
Heart Failure During the Trial
Variable
With
(n = 457)
Without
(n = 14 214)
Age, mean (SD), y 68.5 (7.6) 65.4 (8.0)
Female sex, % 25.2 29.4
Race/ethnicity, %
White 76.6 67.6
Black 6.8 2.9
Asian 11.4 22.6
Other 5.3 6.9
Not Hispanic or Latino 91.5 87.6
Hispanic or Latino 8.5 12.4
Region, %
North America 28.7 17.3
Latin America 5.9 10.2
Western Europe 13.8 14.2
Eastern Europe 26.3 27.1
Asia Pacific or other 25.4 31.3
Diabetes duration, mean (SD), y 12.3 (8.7) 11.6 (8.1)
Glycated hemoglobin, mean (SD), % 7.3 (0.5) 7.2 (0.5)
Glycated hemoglobin category, %
<7% 35.2 33.9
≥7 to <7.5% 27.1 30.8
≥7.5% 37.6 35.2
eGFR, mean (SD), mL/min/1.73 m2 66.5 (20.9) 75.2 (21.1)
Prior vascular disease, %
Coronary artery disease 85.3 73.7
Myocardial infarction 58.2 42.1
Cerebrovascular 29.1 24.3
Peripheral artery 17.3 16.6
Prior heart failure, % 41.8 17.3
Baseline heart failure severity among those
with prior heart failure, %
NYHA class I 18.8 20.4
NYHA class II 39.3 50.4
NYHA class III 16.8 13.4
NYHA class IV 1.6 0.4
NYHA class not reported 23.6 15.4
Blood pressure, mean (SD), mm Hg
Systolic 134.0 (19.4) 135.1 (16.9)
Diastolic 74.4 (11.2) 77.3 (10.4)
Weight, mean (SD), kg 89.6 (20.4) 84.9 (18.9)
Body mass index, mean (SD)a 31.4 (6.3) 30.2 (5.6)
Cigarette smoking, %
Current 11.4 11.4
Former 47.9 39.6
Never 40.7 49.0
Antihyperglycemic therapies, %
Metformin 72.2 81.9
Sulfonylurea 46.2 45.3
Thiazolidinedione 2.8 2.7
Insulin 32.4 22.9
(continued)
Table 1. Baseline Characteristics of Patients in the TECOS Intent-to-Treat
Population, Stratified by ThoseWith vsWithout First Hospitalization for
Heart Failure During the Trial (continued)
Variable
With
(n = 457)
Without
(n = 14 214)
Cardiovascular medications, %
Statin 83.6 79.8
Aspirin 74.6 78.6
Nonaspirin antiplatelet agent 21.7 21.7
ACE inhibitor or angiotensin receptor
blocker
85.6 78.5
β-Blocker 71.8 63.3
Diuretic 69.1 40.1
Calcium channel blocker 39.2 33.6
Abbreviations: ACE, angiotensin-converting enzyme; eGFR, estimated
glomerular filtration rate; NYHA, New York Heart Association; TECOS, Trial
Evaluating Cardiovascular OutcomesWith Sitagliptin.
a Calculated as weight in kilograms divided by height in meters squared.
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The TECOS findings do not confirm the signals for in-
creased risk of hHF observed in 2 previous large DPP4i trials.
The SAVOR-TIMI 53 trial10 assessed the effects of saxagliptin
vsplaceboonhHF inpatientswithT2DM, andahistory or risk
ofCVevents showedanunexpected27%increasedrisk forhHF
(HR, 1.27; 95% CI, 1.07-1.51) associated with saxagliptin use.
The EXAMINE trial11 of alogliptin vs placebo in patients with
T2DM and a recent acute coronary syndrome event showed a
nonsignificant numerical increase of hHF associated with
alogliptin use (HR, 1.19; 95% CI, 0.90-1.58). Previous
meta-analyses12,13 ofDPP4i agents, including saxagliptin, alo-
gliptin, linagliptin, vildagliptin, and sitagliptin, have shown
statistically significant increased pooled estimates of DPP4i-
associated risks for hHF of 24% to 25%. In contrast, meta-
analysis herein limited to the TECOS findings and those from
the SAVOR-TIMI 53 and EXAMINE trials showed a nonsignifi-
cant 14% increase. This meta-analysis is not intended to be a
comprehensive systematic reviewof all DPP4i effects onhHF.
Rather, the objectives are to capitalize on the commonality of
these trial designs (using placebo controls and targeting gly-
cemic equipoise between the groups) and the similarities of
the patient populations enrolled (with prospective capture
and central adjudication of hHF events using virtually iden-
tical processes and outcome definitions) and to place the
present results into the context of a similar meta-analysis10
of the SAVOR-TIMI 53 and EXAMINE trial outcomes previ-
ously published. Given the moderate heterogeneity in this
analysis, important differences across the DPP4i class can-
not be excluded.
It isunclearwhyunexpectedsignals for increasedhHFrisk
were seen with saxagliptin, as well as a similar adverse trend
observedwith alogliptin, comparedwith the neutral effect of
sitagliptin in TECOS. Differences in the trial populations are
unlikely to explain the discordant hHFoutcomes. The TECOS
population had well-managed CV and glycemic risk factors
at entry and was broadly similar to those studied in the
EXAMINE and SAVOR-TIMI 53 trials with regard to baseline
characteristics and the use of background antihyperglycemic
and CVmedications (eTable 2 in the Supplement).14,17-19 The
annualizedhHFratesobservedacross these trialswere lowand
comparable (1.1%, 1.3%, and 2.3% in TECOS, SAVOR-TIMI 53,
andEXAMINE, respectively). TECOSandSAVOR-TIMI 53both
enrolled patients with previous atherosclerotic vascular dis-
ease, although 21% (n = 3533) of the trial cohort in SAVOR-
TIMI 53 hadmultiple CV risk factors only. The EXAMINE trial
enrolled patients at higher CV risk after recent acute coro-
nary syndrome events, as evidenced by their numerically
higher annualized hHF. Previous CV diseasewas an indepen-
dent predictor for hHF in the SAVOR-TIMI 53 trial,10 but no
heterogeneitywas seen for theeffectof saxagliptinonhHFrisk
when analyses were stratified by prevalent CV disease.
In TECOS, 2643 patients (18.0%) had prior HF compared
with2105patients (12.8%) in the SAVOR-TIMI 53 trial and 1533
patients (28.9%) in the EXAMINE trial. In all 3 trials, patients
Table 2. Heart Failure–Related Outcomes for Sitagliptin vs Placebo in the TECOS Intent-to-Treat Population
and in the Subset of PatientsWith Prior Heart Failure at Baseline
Variable
No./Total No. (%)
HR (95% CI) P Value
Sitagliptin
(n = 7332)
Placebo
(n = 7339)
Overall Intent-to-Treat Population
First hospitalization for heart failure
(unadjusted)
228 (3.1) 229 (3.1) 1.00 (0.83-1.19) .95
Adjusted for region and prior heart failure
at baseline
NA NA 1.00 (0.83-1.20) .98
Multivariable adjusteda NA NA 1.02 (0.83-1.26) .82
Composite of hospitalization for heart failure
or cardiovascular death (unadjusted)
538 (7.3) 525 (7.2) 1.02 (0.90-1.14) .81
Adjusted for region and prior heart failure
at baseline
NA NA 1.02 (0.90-1.15) .74
Composite of hospitalization for heart failure
or all-cause death (unadjusted)
685 (9.3) 682 (9.3) 1.00 (0.90-1.11) .93
Total hospitalization for heart failure events
(first plus recurrent) (unadjusted)b
345 347 1.00 (0.80-1.25) >.99
Patients with 2 events 37 44 NA NA
Patients with ≥3 events 26 25 NA NA
Death during or after first hospitalization for
heart failure (unadjusted)
Cardiovascular death 51/228 (22.4) 53/229 (23.1) NA NA
All-cause death 68/228 (29.8) 66/229 (28.8) NA NA
Subset of Patients With Prior Heart Failure at Baseline
First hospitalization for heart failure
(unadjusted)
97/1303 (7.4) 94/1340 (7.0) 1.03 (0.77-1.36) .86
Cardiovascular death (unadjusted) 120/1303 (9.2) 133/1340 (9.9) 0.91 (0.71-1.17) .46
Composite of hospitalization for heart failure
or cardiovascular death (unadjusted)
183/1303 (14.0) 191/1340 (14.3) 0.96 (0.79-1.18) .71
All-cause death 166/1303 (12.7) 182/1340 (13.6) 0.92 (0.75-1.14) .46
Abbreviations: eGFR, estimated
glomerular filtration rate; HR, hazard
ratio; NA, not applicable; TECOS, Trial
Evaluating Cardiovascular Outcomes
With Sitagliptin.
a Adjusted for ethnicity, race, prior
myocardial infarction, coronary
stenosis exceeding 50%, prior
coronary artery bypass graft
surgery, prior peripheral arterial
disease, prior heart failure, cigarette
smoking, diuretic use, age, body
mass index, systolic blood pressure,
diastolic blood pressure, eGFR,
glycated hemoglobin, high-density
lipoprotein cholesterol, and
triglycerides and stratified by
region.
bAnalyzed using themethod of
Andersen and Gill.16
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with prior HF were at increased risk for hHF but with no evi-
dence for heterogeneity of theDPP4i effect by priorHF in any
of the trials,10,11 making it unlikely that different proportions
of patientswithpriorHFacross the 3 trials account for thedis-
cordanthHF findings.TheSAVOR-TIMI53andEXAMINEtrials
allowed higher A1c levels at trial entry (up to 12% and 11%, re-
spectively) in contrast to the TECOS upper limit of 8%. How-
ever, in both TECOS and SAVOR-TIMI 53, there was no asso-
Figure 1. Kaplan-Meier Plots
12.5
10.0
7.5
5.0
2.5
5
4
3
2
1
10
8
6
4
2
0
0 4842
%
 o
f P
at
ie
nt
s W
ith
 a
n 
Ev
en
t
Time in the Trial, mo
4 8 12 18 24 30 36
First hospitalization for heart failureA
No. at risk
7189
7204
7036
7025
6917
6903
6780
6712
6619
6549
4728
4599
3515
3443
2175
2131
1324
1315
7332
7339
Sitagliptin
Placebo
Sitagliptin
Placebo
0
0 4842
%
 o
f P
at
ie
nt
s W
ith
 a
n 
Ev
en
t
Time in the Trial, mo
4 8 12 18 24 30 36
Composite of hospitalization for heart failure or cardiovascular deathB
No. at risk
7178
7190
7024
7003
6895
6882
6755
6684
6593
6517
4707
4579
3501
3425
2165
2117
1320
1307
7332
7339
Sitagliptin
Placebo
0
0 4842
%
 o
f P
at
ie
nt
s W
ith
 a
n 
Ev
en
t
Time in the Trial, mo
4 8 12 18 24 30 36
Composite of hospitalization for heart failure or all-cause deathC
No. at risk
7178
7191
7025
7006
6895
6885
6755
6686
6593
6519
4707
4581
3502
3425
2165
2117
1320
1307
7332
7339
Sitagliptin
Placebo Treatment with sitagliptin is
compared with placebo.
Association Between Sitagliptin Use and Heart Failure Hospitalization Original Investigation Research
jamacardiology.com (Reprinted) JAMA Cardiology May 2016 Volume 1, Number 2 131
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
Figure 2. Stratified Analyses for Sitagliptin vs Placebo on First Hospitalization for Heart Failure for Prespecified and Post Hoc
or Exploratory Subgroups
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Bodymass index is calculated as weight in kilograms divided by height in meters squared. ACE indicates angiotensin-converting enzyme; eGFR, estimated
glomerular filtration rate; HR, hazard ratio; and NYHA, New York Heart Association.
a Post hoc subgroups.
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ciationbetweenbaselineA1c level andhHF risk, norwas there
heterogeneity of the effect of study drug on hHF events by
baseline A1c level in either trial.
Differences in trial durationmight influence detection of
a risk signal for hHF, with TECOS having the longest duration
of theDPP4i trials reported todate. Themedian follow-uppe-
riods for death were 3.0 years in TECOS, 1.9 years in SAVOR-
TIMI 53, and 1.5 years in EXAMINE. In this regard, it is no-
table that in the SAVOR-TIMI 53 trial the greatest incremental
risk for hHFwasobserved early in the trial. Saxagliptin vs pla-
cebo showedhHFHRs of 1.80 (95%CI, 1.29-2.55) at 6months
and1.46 (95%CI, 1.15-1.88) at 12months,declining to 1.27 (95%
CI, 1.07-1.51) at trial end,with significant heterogeneity of the
effect size by time (P = .02 for interaction). No such time-
varying heterogeneity was observed with the sitagliptin ef-
fects on hHF in TECOS.
There was uniform prospective ascertainment and cen-
tral adjudicationofhHFthroughout theTECOSusing the same
definition as the SAVOR-TIMI 53 and EXAMINE trials,10,11 ex-
cluding another possible cause of the discordant hHF find-
ings. While many of the hHF-related analyses in the SAVOR-
TIMI 53 andEXAMINE trialswere post hoc, eachof the 3 trials
identified hHF as a prespecified secondary analysis. Unex-
pected SAVOR-TIMI 53 and EXAMINE hHF findings reported
during the conduct of TECOS led to the development of a for-
malHFstatistical analysisplanbefore trial completionandun-
masking. While this a priori planning yields some incremen-
tal statistical conservatism, our analysis methods largely
parallel and extend those reported from the SAVOR-TIMI 53
andEXAMINEtrials.Accordingly, statistical limitationsareun-
likely to account for the discordance in hHF findings.
To date, there has been no clear explanation as to the
mechanisms by which some DPP4i agents might increase HF
risk. It ispossible thatDPP4ipharmacologicaldifferencescould
account for the differential hHF risks, which was evident
for example with the thiazolidinediones, for which a
meta-analysis6 demonstrated within-class qualitative differ-
ences for HF risk. Most important for the thiazolidinediones,
other markers of HF are also affected, including higher rates
of peripheral edema, weight gain, and increased circulating
brain natriuretic peptide (BNP),5,20 while no such associa-
tions have been reported for the DPP4i class. In the SAVOR-
TIMI 53 trial, N-terminal pro-BNP increased slightly in both
randomized groups, with a slightly greater mean increase in
the placebo group compared with the saxagliptin group.10
In the EXAMINE trial, BNP declined slightly in both ran-
domized groups, with no difference between alogliptin and
placebo.11 Natriuretic peptide assessments are not presently
available from TECOS. Sitagliptin use was not associated
with increased weight in TECOS (eFigure 1D in the Supple-
ment), with similar neutral weight effects of saxagliptin and
alogliptin in the SAVOR-TIMI 53 and EXAMINE trials,
respectively.10,17 However, given the absence of adverse
DPP4i effects on weight in these 3 trials and on natriuretic
peptides in SAVOR-TIMI 53 and EXAMINE, the interpreta-
tion of these observations is limited.
It remainspossible that the increasedhHFobserved in the
SAVOR-TIMI53 trial andthenumerical imbalance inhHFfound
in the EXAMINE trial are due to chance, with analyses largely
post hoc and not adjusted for multiplicity of comparisons or
controlled for type I error. However, this possibility remains
an unlikely explanation for the discordant observations be-
tween the trials. Despite the uncertain statistical validity in-
herent in post hoc analyses, the validity of the observation in
the SAVOR-TIMI 53 trial is supported by the large number of
hHF events (n = 517) (yielding robust statistical power), the
prospective collection and adjudication of hHF events, and
the time-dependent increase in hHF emerging soon after
study drug initiation. This validity is supported, although
not proved, by previously published meta-analyses12,13 of
data from these trials and others evaluating the effect of
DPP4i agents on HF risk.
The present results have certain limitations. TECOS in-
cluded patients with well-controlled glucose levels and ex-
cludedpatientswithseverekidneydysfunction.Therefore, the
present observationsmay not apply to patients with such ex-
clusioncriteria.However, no increased riskwasobservedwith
sitagliptin use among those with baseline mild or moderate
kidney impairment. Although designed to achieve balance in
glycemic control between the groups, therewas amean 0.3%
lower A1c level in the sitagliptin group over the trial duration,
which could confound the direct drug effects with the glyce-
mic effects on the outcomes assessed. Limited clinical detail
is available for the hHF events, with no imaging information
available on cardiac structure and function, and other objec-
tive measures of HF, such as measurement of circulating na-
triuretic peptides, were not captured. The trial duration was
longer than most trials assessing antihyperglycemic medica-
tions reported todate,with a follow-upperiodofup to5years,
but the longer-term CV safety and efficacy of sitagliptin
Figure 3. Meta-Analysis of SAVOR-TIMI 53, EXAMINE, and TECOS
0 21
HR
First hospitalization for heart failureA
HR (95% CI) P Value
Favors
DPP4i
Favors
Placebo
SAVOR-TIMI 53 1.27 (1.07-1.51) .007
EXAMINE 1.19 (0.89-1.59) .24
TECOS 1.00 (0.84-1.20) >.99
SAVOR-TIMI 53 plus
EXAMINE plus TECOS
(P = .16, I2 = 44.9)
1.14 (0.97-1.34) .10
0 21
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Composite of hospitalization for heart failure or cardiovascular deathB
HR (95% CI) P Value
Favors
DPP4i
Favors
Placebo
SAVOR-TIMI 53 1.14 (1.00-1.30) .05
EXAMINE 1.00 (0.82-1.22) >.99
TECOS 1.02 (0.90-1.14) .81
SAVOR-TIMI 53 plus
EXAMINE plus TECOS
(P = .36, I2 = 1.29)
1.06 (0.98-1.15) .18
DPP4i indicates dipeptidyl peptidase 4 inhibitor; EXAMINE, Examination of
Cardiovascular OutcomesWith Alogliptin vs Standard of Care; HR, hazard ratio;
SAVOR-TIMI 53, Saxagliptin Assessment of Vascular Outcomes Recorded in
Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53;
and TECOS, Trial Evaluating Cardiovascular OutcomesWith Sitagliptin.
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cannot be assessed. Exploratory analyses planned in the
supplemental HF statistical analysis plan were additional to
those planned at the start of the trial and not analyzed under
strict hierarchical statistical testingplanned for keyendpoints
associatedwith hypotheses. Limitations of themeta-analysis
include overall low hHF event rates (despite the large sample
sizes of the trials), limited participation in each of the trials of
patientswith priorHF (13%-28%across the trials), and a short
median follow-up duration for each of the trials (range, 1.5-3
years), precluding the ability to assess longer-term effects. In
addition, although hHF events were prospectively captured
and centrally adjudicated using similar processes and com-
mon definitions across each of the 3 trials, all of the hHF
results reported derive from post hoc, exploratory analyses.
Therefore, the findings should be interpreted carefully be-
cause these analyses were not adjusted for multiplicity.
Conclusions
The resultsof thepresentanalysesdemonstrate that sitagliptin
use did not affect the risk for hHF or related adverse clinical
outcomes, overall or across selected subgroups of interest.
In the context of the primary findings from TECOS that dem-
onstrated noninferiority of the effects of sitagliptin vs pla-
cebo onmajor atherosclerotic adverse CV events, the present
results provide further support that sitagliptin may be safely
used in a population of patients with T2DM at high CV risk.
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